Mail

UK markets close in 3 hours 34 minutes

FTSE 100
6,657.69
-57.73(-0.86%)
FTSE 250
20,598.76
-194.96(-0.94%)
AIM
1,192.44
-5.65(-0.47%)

US drug authority approves world's first long-acting HIV regimen

Cabenuva's injectable HIV treatment regimen — which is administered once a month — does not require daily pills

Vivendi SA (VIV.PA)

Paris - Paris Delayed price. Currency in EUR

Add to watchlist

26.34-0.27 (-1.01%)

As of 1:39PM CET. Market open.

Currency in EUR

Earnings estimate	Current qtr. (Mar 2018)	Next qtr. (Jun 2018)	Current year (2018)	Next year (2019)
No. of analysts	0	0	0	0
Avg. Estimate	0	0	0	0
Low estimate	0	0	0	0
High estimate	0	0	0	0
Year ago EPS	0.12	0.13	N/A	N/A

Revenue estimate	Current qtr. (Mar 2018)	Next qtr. (Jun 2018)	Current year (2018)	Next year (2019)
No. of analysts	2	3	20	20
Avg. Estimate	3.11B	3.35B	13.78B	14.63B
Low estimate	3.11B	3.37B	13.53B	13.95B
High estimate	3.13B	3.4B	14B	15.42B
Year ago sales	2.66B	2.77B	12.44B	13.78B
Sales growth (year/est)	16.70%	20.90%	10.80%	6.10%

Earnings history	31/03/2017	30/06/2017	30/09/2017	31/12/2017
Est. EPS	0.1	0.15	0.21	0.27
Actual EPS	0.12	0.13	0.22	0.53
Difference	0.02	-0.02	0.01	0.26
Surprise %	20.00%	-13.30%	4.80%	96.30%

EPS trend	Current qtr. (Mar 2018)	Next qtr. (Jun 2018)	Current year (2018)	Next year (2019)
Current estimate	0	0	0	0
7 days ago	0.16	0.18	0.88	1.05
30 days ago	0.16	0.18	0.88	1.05
60 days ago	0.16	0.18	0.88	1.05
90 days ago	0.16	0.18	0.88	1.05

EPS revisions	Current qtr. (Mar 2018)	Next qtr. (Jun 2018)	Current year (2018)	Next year (2019)
Up last 7 days	N/A	N/A	N/A	N/A
Up last 30 days	N/A	N/A	1	2
Down last 7 days	N/A	N/A	N/A	N/A
Down last 30 days	N/A	N/A	N/A	N/A

Growth estimates	VIV.PA	Industry	Sector(s)	S&P 500
Current qtr.	N/A	N/A	N/A	N/A
Next qtr.	N/A	N/A	N/A	N/A
Current year	N/A	N/A	N/A	N/A
Next year	N/A	N/A	N/A	N/A
Next 5 years (per annum)	6.64%	N/A	N/A	N/A
Past 5 years (per annum)	N/A	N/A	N/A	N/A